GETI.B

209.1

+1.7%↑

CAMX

609

+2.78%↑

BIOAB

320.6

+1.84%↑

EKTA.B

55.85

+3.04%↑

VITR

138.6

+0.36%↑

GETI.B

209.1

+1.7%↑

CAMX

609

+2.78%↑

BIOAB

320.6

+1.84%↑

EKTA.B

55.85

+3.04%↑

VITR

138.6

+0.36%↑

GETI.B

209.1

+1.7%↑

CAMX

609

+2.78%↑

BIOAB

320.6

+1.84%↑

EKTA.B

55.85

+3.04%↑

VITR

138.6

+0.36%↑

GETI.B

209.1

+1.7%↑

CAMX

609

+2.78%↑

BIOAB

320.6

+1.84%↑

EKTA.B

55.85

+3.04%↑

VITR

138.6

+0.36%↑

GETI.B

209.1

+1.7%↑

CAMX

609

+2.78%↑

BIOAB

320.6

+1.84%↑

EKTA.B

55.85

+3.04%↑

VITR

138.6

+0.36%↑

Kodu・Aktsiate loetelu・Vivesto AB

Vivesto AB

Suletud

0.22

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.22

Max

0.22

Põhinäitajad
By Trading Economics
Sissetulek	2.3M -7.2M
Aktsiakasum	-0.013
Töötajad	4

Turustatistika
By TradingEconomics
Turukapital	-8.3M 70M
Eelmine avamishind	0.22
Eelmine sulgemishind	0.22

Vivesto AB Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. dets 2025, 23:03 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11. dets 2025, 21:50 UTC

Tulu

Costco Same-Store Sales, Membership Fees Rose in 1Q

11. dets 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

11. dets 2025, 23:44 UTC

Market Talk

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11. dets 2025, 23:43 UTC

Omandamised, ülevõtmised, äriostud

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11. dets 2025, 23:41 UTC

Tulu

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11. dets 2025, 23:37 UTC

Market Talk

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11. dets 2025, 23:31 UTC

Tulu

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11. dets 2025, 22:48 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11. dets 2025, 22:35 UTC

Tulu

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11. dets 2025, 22:30 UTC

Tulu

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11. dets 2025, 22:09 UTC

Omandamised, ülevõtmised, äriostud

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11. dets 2025, 22:05 UTC

Tulu

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11. dets 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

11. dets 2025, 21:39 UTC

Tulu

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11. dets 2025, 21:39 UTC

Tulu

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11. dets 2025, 21:38 UTC

Tulu

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11. dets 2025, 21:37 UTC

Tulu

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11. dets 2025, 21:37 UTC

Market Talk

Broadcom Sees AI Revenue Doubling -- Market Talk

11. dets 2025, 21:34 UTC

Omandamised, ülevõtmised, äriostud

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11. dets 2025, 21:29 UTC

Omandamised, ülevõtmised, äriostud

Dexus Aiming for Long-Term Holding of A$50M in Fund

11. dets 2025, 21:28 UTC

Market Talk

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Dexus: Third Party Investors to Contribute Remainder

11. dets 2025, 21:27 UTC

Omandamised, ülevõtmised, äriostud

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11. dets 2025, 21:25 UTC

Omandamised, ülevõtmised, äriostud

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Võrdlus sarnastega

Hinnamuutus

Vivesto AB Prognoos

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.